Overall Survival Versus Progression-Free Survival in Oncology Clinical Trials
نویسندگان
چکیده
منابع مشابه
Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.
BACKGROUND The use of auxiliary endpoints may provide efficiencies for clinical trial design, but such endpoints may not have intrinsic clinical relevance or clear linkage to more meaningful endpoints. The purpose of this study was to generate a novel endpoint that considers both overall survival (OS) and earlier events such as progression-free survival (PFS) and determine whether such an endpo...
متن کاملProgression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
BACKGROUND The aim of this study was to determine correlations between progression-free survival (PFS) and the objective response rate (ORR) with overall survival (OS) in glioblastoma and to evaluate their potential use as surrogates for OS. METHOD Published glioblastoma trials reporting OS and ORR and/or PFS with sufficient detail were included in correlative analyses using weighted linear r...
متن کاملProgression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.
The traditional endpoint for assessing efficacy of chemotherapies for advanced/recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and thr...
متن کاملOngoing Clinical Trials Ot-01. Is Surgery at Progression a Prognostic Marker for Improved 6-month Progression-free Survival or Overall Survival for Patients with Recurrent Glioblastoma?
Historically, the North American Brain Tumor Consortium (NABTC) has used 6-month progression-free survival (PFS6) as the primary endpoint of Phase II clinical trials for recurrent glioma. Measurable disease has not been required and patients with recent surgeries have been eligible. In some trials, a subset of patients has received the trial agent before surgery to allow for the assessment of t...
متن کاملEstimating changes in overall survival using progression-free survival in metastatic breast and colorectal cancer.
OBJECTIVES In clinical trials of new cancer drugs, reliable data for progression-free survival will often become available far sooner than reliable data for overall survival. The aim of this study was to determine how many months it would be expected that any given new drug for metastatic breast or colorectal cancer will add to overall survival times given that the number of months the drug add...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2016
ISSN: 1098-3015
DOI: 10.1016/j.jval.2016.09.2124